News & Updates

Show Multimedia Only

Ruxolitinib improves repigmentation in vitiligo through 52 weeks

21 Oct 2022 by

Long-term use of ruxolitinib cream continued to improve facial and total body repigmentation in patients with nonsegmental vitiligo from 24 to 52 weeks, according to an updated pooled analysis of the phase III TRuE-V1* and TRuE-V2** studies presented at EADV 2022.

21 Oct 2022

Dupilumab reduces itch, improves skin lesions in prurigo nodularis

20 Oct 2022 by

Dupilumab improves itch response and skin lesions in patients with prurigo nodularis (PN) inadequately controlled with prior therapies in the LIBERTY-PN PRIME trial.

20 Oct 2022

SLN status delivers vital prognosis in stage IIB/C cutaneous melanoma

17 Oct 2022

The status of sentinel lymph nodes (SLN) can help predict the course of the disease in patients with clinical stage IIB/C cutaneous melanoma, suggests a study.

17 Oct 2022

Alopecia areata tied to higher risk of retinal diseases

17 Oct 2022

The risk of retinal disease seems to be greater among patients with alopecia areata (AA), according to a nationwide population-based cohort study.

17 Oct 2022

Comorbidity burden heavier in generalized pustular psoriasis

17 Oct 2022

Patients with generalized pustular psoriasis (GPP) suffer from a heavier burden of comorbidities than the general population and comparators with psoriasis vulgaris (PV), a new study has found.

17 Oct 2022

Timely treatment of melanoma helps improve patient survival

16 Oct 2022

Delays in the treatment of melanoma may worsen overall (OM) and melanoma-specific mortality (MSM), suggest the results of a recent study.

16 Oct 2022

Skin type factors in dupilumab efficacy in atopic dermatitis

15 Oct 2022

The use of dupilumab in the treatment of atopic dermatitis appears to benefit patients who have dark skin types more than those who have light skin types, as shown in a study.

15 Oct 2022

Lebrikizumab efficacy in atopic dermatitis maintained at 1 year

12 Oct 2022 by

Maintenance lebrikizumab monotherapy appears to improve outcomes in patients with moderate-to-severe atopic dermatitis (AD), according to results of the phase III ADvocate1 and ADvocate2 trials.

12 Oct 2022

Subcutaneous, sublingual immunotherapy to aeroallergens helps with atopic dermatitis

08 Oct 2022

The use of sublingual (SLIT) or subcutaneous (SCIT) immunotherapy against aeroallergens can help improve disease severity and quality of life (QoL) among patients with atopic dermatitis (AD), reports a recent meta-analysis.

08 Oct 2022

Sensitization, dermatitis prevalent among workers highly exposed to epoxy

06 Oct 2022

Skin sensitization and dermatitis appear to be common among workers exposed to high concentrations of epoxy, despite comprehensive skin protection, according to a study.

06 Oct 2022

News & Updates

Showing Dermatology articles

Showing

Specialty:

Ruxolitinib improves repigmentation in vitiligo through 52 weeks

Dupilumab reduces itch, improves skin lesions in prurigo nodularis

SLN status delivers vital prognosis in stage IIB/C cutaneous melanoma

Alopecia areata tied to higher risk of retinal diseases

Comorbidity burden heavier in generalized pustular psoriasis

Timely treatment of melanoma helps improve patient survival

Skin type factors in dupilumab efficacy in atopic dermatitis

Lebrikizumab efficacy in atopic dermatitis maintained at 1 year

Subcutaneous, sublingual immunotherapy to aeroallergens helps with atopic dermatitis

Sensitization, dermatitis prevalent among workers highly exposed to epoxy